FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa < sup > ® < /sup > in general practice
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa < sup > ® < /sup > than with warfarin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa < sup > ® < /sup > )
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
FDA Approves Praxbind < sup > ® < /sup > (idarucizumab), Specific Reversal Agent for Pradaxa < sup > ® < /sup > (dabigatran etexilate)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa < sup > ® < /sup > (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Safety and efficacy of Pradaxa < sup > ® < /sup > (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Efficacy and Safety Profile of Pradaxa < sup > ® < /sup > (dabigatran etexilate) Repeatedly Confirmed
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa < sup > ® < /sup > (dabigatran etexilate) specific investigational antidote
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Pradaxa < sup > ® < /sup > (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY < sup > ® < /sup > – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New long-term data reinforce safety profile of Pradaxa < sup > ® < /sup > for stroke prevention in AF
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New data analyses show consistent efficacy and safety profile of Pradaxa < sup > ® < /sup > in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa < sup > ® < /sup > in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
As the benefits and safety of Pradaxa < sup > ® < /sup > (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Antidote for rapid reversal of Pradaxa < sup > ® < /sup > (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
